References
- Alterio V, Di Fiore A, D’Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev 2012;112:4421–68.
- Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168–181.
- Neri D, Supuran CT. Interfering with pH regulation in tumors as a therapeutic strategy. Nat Rev Drug Discov 2011;10:767–77.
- Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011;11:393–410.
- McDonald PC, Winum JY, Supuran CT, Dedhar S. Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget 2012;3:84–97.
- Palmer C, Supuran CT. A Key Opinion Leader interview: insight into the research and career of Prof. Claudiu T Supuran. Expert Opin Ther Pat 2015;25:501–5.
- Winum JY, Scozzafava A, Montero JL, Supuran CT. Design of zinc binding functions for carbonic anhydrase inhibitors. Curr Pharm Des 2008;14:615–21.
- Krasavin M, Korsakov M, Dorogov M, et al. Probing the ‘bipolar’ nature of the carbonic anhydrase active site: aromatic sulfonamides containing 1,3-oxazol-5-yl moiety as picomolar inhibitors of cytosolic CA I and CA II isoforms. Eur J Med Chem 2015;101:334–47.
- Pacchiano F, Aggarwal M, Avvaru BS, et al. Selective hydrophobic pocket binding observed within the carbonic anhydrase II active site accommodate different 4-substituted-ureidobenzenesulfonamides and correlate to inhibitor potency. Chem Commun 2010;46:8371–3.
- Supuran CT. Structure-based drug discovery of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2012;27:759–72.
- Tanpure RP, Ren B, Peat TS, et al. Carbonic anhydrase inhibitors with dual-tail moieties to match the hydrophobic and hydrophilic halves of the carbonic anhydrase active site. J Med Chem 2015;58:1494–501.
- Sarnpitak P, Mujumdar P, Morisseau C, et al. Potent, orally available, selective COX-2 inhibitors based on 2-imidazoline core. Eur J Med Chem 2014;84:160–72.
- De Monte C, Carradori S, Gentili A, et al. Dual cyclooxygenase and carbonic anhydrase inhibition by nonsteroidal anti-inflammatory drugs for the treatment of cancer. Curr Med Chem 2015;22:2812–18.
- Krasavin M. Novel diversely substituted 1-heteroaryl-2-imidazolines for fragment-based drug discovery. Tetrahedron Lett 2012;53:2876–80.
- Krasavin M. Pd-catalyzed N-arylation of 2-imidazolines provides convenient access to selective cyclooxygenase-2 inhibitors. Lett Org Chem 2013;10:235–9.
- Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. J Biol Chem 1971;246:2561–73.
- Maresca A, Carta F, Vullo D, Supuran CT. Dithiocarbamates strongly inhibit the β-class carbonic anhydrases from Mycobacterium tuberculosis. J Enzyme Inhib Med Chem 2013;28:407–11.
- Ekinci D, Kurbanoglu NI, Salamci E, et al. Carbonic anhydrase inhibitors: inhibition of human and bovine isoenzymes by benzenesulphonamides, cyclitols and phenolic compounds. J Enzyme Inhib Med Chem 2012;27:845–8.
- Ekinci D, Karagoz L, Ekinci D, et al. Carbonic anhydrase inhibitors: in vitro inhibition of α isoforms (hCA I, hCA II, bCA III, hCA IV) by flavonoids. J Enzyme Inhib Med Chem 2013;28:283–8.
- Alp C, Maresca A, Alp NA, et al. Secondary/tertiary benzenesulfonamides with inhibitory action against the cytosolic human carbonic anhydrase isoforms I and II. J Enzyme Inhib Med Chem 2013;28:294–8.
- Mujumdar P, Sarnpitak P, Shetnev A, et al. Pd-catalyzed amination of imidazolin-1-yl azines: toward a new kinase-inhibitory chemotype. Tetrahedron Lett 2015;56:2827–31.
- Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem 2016;31:345–60.